

Blueberry Therapeutics (Blueberry) today announced that it has started collaborating with The University of Sheffield and Sheffield Hallam University to explore development of new anti-fungal drugs and treatments. This collaborative project brings together leading academics at both of Sheffield's world-class universities with Blueberry's drug discovery and development expertise and will explore the development of new drugs and treatments for a wide range of fungal infections. The collaboration is supported by the Higher Education Innovation Fund (HEIF) from both Sheffield universities.

John Ridden, Chief Executive Officer at Blueberry Therapeutics said, "We are very pleased to be part of this exciting team, which brings together experts from both of Sheffield's universities with the common aim of developing new treatments for fungal diseases. For us, this kind of collaboration is a great example of how working together we can tackle difficult unmet problems in healthcare."

The academic team is led by Dr Graham Stafford and Dr Simon Jones (University of Sheffield) and Professor Tom Smith (Sheffield Hallam University). Speaking on behalf of the team from both Universities, Dr Jones, a Reader in Synthetic Organic Chemistry at the University of Sheffield, added, "It's an exciting prospect to see how expertise and innovation originating from fundamental scientific research can be applied in new commercial ventures. The project is a clear demonstration of the collaborative research environment at both institutions in Sheffield."

**ENDS**

## **NOTES TO EDITORS**

### **About Blueberry Therapeutics**

Blueberry Therapeutics is an innovation driven Biopharmaceutical Company whose ambition is to exploit advances in nanotechnology to deliver new therapeutic approaches that meet unmet medical needs. Blueberry delivers projects from preclinical research to clinical proof of concept and beyond in both humans and companion animal diseases. Successful programs will then be partnered with major pharmaceutical companies for further development and marketing. Blueberry has a healthy R&D portfolio including novel anti-fungal projects that are approaching Phase 3. For more information please visit: [www.blueberrytherapeutics.com](http://www.blueberrytherapeutics.com)